Xilio Therapeutics, Inc. (XLO)
After hours:
| Previous close | 1.0800 |
| Open | 1.1000 |
| Bid | 1.1100 x 100 |
| Ask | 1.2000 x 100 |
| Day's range | 1.0600 - 1.1800 |
| 52-week range | 0.4900 - 3.2500 |
| Volume | |
| Avg. volume | 1,244,553 |
| Market cap | 42.08M |
| Beta (5Y monthly) | -0.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14, 2024 (
- GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Granted Gilead exclusive license to develop and commercialize XTX301, a tumor-activated IL-12 Anticipates cash runway into the second quarter of 2025 WALTHAM, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnolo
- GlobeNewswire
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager moleculesReports additional Phase 2 data for XTX202, a tumor-activated, beta-gamma biased IL-2, supporting potential as combination therapy; plans to discontinue monotherapy development and evaluate
